The Future of Aging, AI, and Robotics with CEO of Insilico Medicine
Insilico Medicine’s mission is to extend healthy, productive longevity by transforming drug discovery and development with generative artificial intelligence.
Insilico Medicine’s mission is to extend healthy, productive longevity by transforming drug discovery and development with generative artificial intelligence.
The pursuit of novel cures in the pharmaceutical industry has always been a challenging endeavor. However, within the last decade or so, the landscape has become even more complex and disruptive due to several key factors. In this blog, we explore four major disruptions impacting the hunt for new cures and how artificial intelligence (AI)…
“In this episode, Alok shares his personal story of how medical conditions in his family led to the creation of Vibe Bio, and how the company aims to identify diseases with unmet needs, leveraging AI to find medicines with the highest chances of providing cures.”
Sandra Shpilberg, Co-founder and CEO of Adnexi, discusses using AI to develop effective strategies for biopharma key expert and digital opinion leader selection to elevate your product launch.
Frank Gleeson, Co-Founder and CEO of Satellos Bioscience, discusses groundbreaking small molecule therapies for Duchenne muscular dystrophy.
The Impact Review article explores Alok Tayi’s personal experience with rare disease drove him towards a mission – to fund cures for rare diseases.
Learn how Vibe Bio is tackling the problem of funding & guiding high potential drug programs.
This article examines how Vibe Bio’s Founder and CEO is putting drug development into patients’ hands.